Soligenix Advances COVID-19 Vaccine Candidate CiVax Amid Ongoing Global Health Threat
Soligenix is developing CiVax, a heat-stable COVID-19 vaccine candidate, in response to persistent global health risks from the virus, with recent preclinical studies showing promising protection against multiple variants.
Pharmaceutical company Soligenix continues to develop its COVID-19 vaccine candidate CiVax, addressing ongoing global health challenges posed by the persistent virus. Recent World Health Organization data reveals that between January 6 and February 2, 2025, over 147,000 new COVID-19 cases were reported globally, accompanied by approximately 4,500 new deaths—representing a 28% increase in fatalities.
Preclinical studies of CiVax have demonstrated the vaccine's potential to induce rapid and broad protection against multiple COVID-19 variants. This development is particularly significant as the virus continues to circulate, despite declining case numbers. The Centers for Disease Control and Prevention confirms that acute respiratory illness levels remain low, yet the ongoing threat necessitates continued vaccine research.
The persistent presence of COVID-19 underscores the critical importance of developing adaptable and effective vaccine solutions. CiVax's heat-stable characteristics could provide a significant advantage in vaccine distribution, particularly in regions with limited cold storage infrastructure.